将“财健道”设为星标持续关注,不错过好看每日医刻1映恩生物与阿斯利康达成合作4月25日。映恩生物宣布,与阿斯利康建立合作,双方将就映恩生物自主研发的HER3ADC创新药DB-1310与阿斯利康的第三代EGFR抑制剂奥希替尼的联合疗法开展临床探索。2总金额超1.12亿美元,复宏汉霖就H药与Lotus达成韩国独家授权合作4月25日,复宏汉霖宣布,与美时化学制药全资子公司Lotus签署授权许可协议,授予...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.